GlassScriptPhysician profile
Sandra L Peach
NPI 1003268897
$1,660.58
in general payments reported to CMS, 2019-2025
18 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $47.73 · 2023: $333 · 2024: $750 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $322.02 | 2023-2025 | Farxiga, Fasenra, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $206.19 | 2022-2025 | |
| Novo Nordisk INC | $154.06 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $132.26 | 2023-2024 | Cologuard Collection Kit |
| Lundbeck LLC | $120.37 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $116.33 | 2023-2025 | |
| Amgen INC. | $110.36 | 2022-2024 | Evenity, Prolia |
| Lilly USA, LLC | $104.95 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Ironshore Pharmaceuticals INC. | $78.72 | 2023-2024 | Jornay Pm |
| Abbvie INC. | $73.28 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $59.97 | 2023-2025 | Rexulti |
| Abbott Laboratories | $53.52 | 2024-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $33.37 | 2024-2025 | Voquezna |
| Dexcom, INC. | $26.24 | 2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $22.55 | 2025 | Omnipod |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.43 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.16 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $13.80 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Peach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.